Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma

Hana Ajouz; Deborah Mukherji; Ali Haydar; Ahmad Sharif Yakan; Ahmad Saleh; Elias Elias; Sally Temraz; Walid Faraj; Mohammad Khalife; Ali Shamseddine

doi:10.1007/s12029-013-9571-x

Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma

Hana Ajouz, Deborah Mukherji, Ali Haydar, Ahmad Sharif Yakan, Ahmad Saleh, Elias Elias, Sally Temraz, Walid Faraj, Mohammad Khalife, Ali Shamseddine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.

Original language	English (US)
Pages (from-to)	109-112
Number of pages	4
Journal	Journal of Gastrointestinal Cancer
Volume	45
Issue number	1
DOIs	https://doi.org/10.1007/s12029-013-9571-x
State	Published - Mar 2014
Externally published	Yes

Keywords

GTX
Pancreatic adenocarcinoma
Second-line chemotherapy

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.1007/s12029-013-9571-x

Cite this

@article{777fdf3c1ebe4458ba9efc0d401190f2,

title = "Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma",

abstract = "Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.",

keywords = "GTX, Pancreatic adenocarcinoma, Second-line chemotherapy",

author = "Hana Ajouz and Deborah Mukherji and Ali Haydar and Yakan, {Ahmad Sharif} and Ahmad Saleh and Elias Elias and Sally Temraz and Walid Faraj and Mohammad Khalife and Ali Shamseddine",

year = "2014",

month = mar,

doi = "10.1007/s12029-013-9571-x",

language = "English (US)",

volume = "45",

pages = "109--112",

journal = "Journal of Gastrointestinal Cancer",

issn = "1941-6628",

publisher = "Humana Press",

number = "1",

}

TY - JOUR

T1 - Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma

AU - Ajouz, Hana

AU - Mukherji, Deborah

AU - Haydar, Ali

AU - Yakan, Ahmad Sharif

AU - Saleh, Ahmad

AU - Elias, Elias

AU - Temraz, Sally

AU - Faraj, Walid

AU - Khalife, Mohammad

AU - Shamseddine, Ali

PY - 2014/3

Y1 - 2014/3

N2 - Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.

AB - Background: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. Methods: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. Conclusion: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.

KW - GTX

KW - Pancreatic adenocarcinoma

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84896318929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896318929&partnerID=8YFLogxK

U2 - 10.1007/s12029-013-9571-x

DO - 10.1007/s12029-013-9571-x

M3 - Article

C2 - 24362621

AN - SCOPUS:84896318929

SN - 1941-6628

VL - 45

SP - 109

EP - 112

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

IS - 1

ER -

Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this